These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Acute loss of vision after an intravitreal injection ocriplasmin: a functional evolutionary study for 1-year follow-up. Gómez-Ulla F; Bande MF; Abraldes M Doc Ophthalmol; 2015 Dec; 131(3):231-5. PubMed ID: 26542118 [TBL] [Abstract][Full Text] [Related]
12. Post-Market Experience With Ocriplasmin Including Chronic Electrophysiologic Changes. Small KW; Shaya FS; La Fontaine M Ophthalmic Surg Lasers Imaging Retina; 2015 Oct; 46(9):956-62. PubMed ID: 26469236 [TBL] [Abstract][Full Text] [Related]
13. RESOLUTION OF SUBRETINAL FLUID AND OUTER RETINAL CHANGES IN PATIENTS TREATED WITH OCRIPLASMIN. Nudleman E; Franklin MS; Wolfe JD; Williams GA; Ruby AJ Retina; 2016 Apr; 36(4):738-43. PubMed ID: 26398688 [TBL] [Abstract][Full Text] [Related]
14. Severe acute vision loss, dyschromatopsia, and changes in the ellipsoid zone on sd-oct associated with intravitreal ocriplasmin injection. Quezada Ruiz C; Pieramici DJ; Nasir M; Rabena M; Avery RL Retin Cases Brief Rep; 2015; 9(2):145-8. PubMed ID: 25462129 [TBL] [Abstract][Full Text] [Related]
15. Early panretinal abnormalities on fundus autofluorescence and spectral domain optical coherence tomography after intravitreal ocriplasmin. Barteselli G; Carini E; Invernizzi A; Ratiglia R; Viola F Acta Ophthalmol; 2016 Mar; 94(2):e160-2. PubMed ID: 26010219 [No Abstract] [Full Text] [Related]
16. Acute vision loss after ocriplasmin use. Reiss B; Smithen L; Mansour S Retin Cases Brief Rep; 2015; 9(2):168-9. PubMed ID: 25741635 [TBL] [Abstract][Full Text] [Related]
17. Improved efficacy of ocriplasmin for vitreomacular traction release and transient changes in optic disk morphology. Willekens K; Abegão Pinto L; Vandewalle E; Stalmans I; Stalmans P Retina; 2015 Jun; 35(6):1135-43. PubMed ID: 25719990 [TBL] [Abstract][Full Text] [Related]
18. Longitudinal ellipsoid zone and subretinal fluid mapping following ocriplasmin injection in the prospective observational ORBIT trial. Lavine JA; Srivastava SK; Dukles N; Reese JL; Ehlers JP Br J Ophthalmol; 2020 Mar; 104(3):410-415. PubMed ID: 31248879 [TBL] [Abstract][Full Text] [Related]
19. Association between anatomical resolution and functional outcomes in the mivi-trust studies using ocriplasmin to treat symptomatic vitreomacular adhesion/vitreomacular traction, including when associated with macular hole. Gandorfer A; Benz MS; Haller JA; Stalmans P; Pakola SJ; Girach A; Kampik A; Toth CA; Jaffe GJ; Retina; 2015 Jun; 35(6):1151-7. PubMed ID: 25741816 [TBL] [Abstract][Full Text] [Related]
20. Vitrectomy After ocriplasmin for VitreOmacular adhesion Or Macular hole (VAVOOM) study. Greven MA; Garg S; Chiu B; Shah SP; Wolfe J; Fine HF; Roth DB; Robinson J; Mong J; Hsu J; Regillo C; Ho A; Haller JA Br J Ophthalmol; 2016 Sep; 100(9):1211-5. PubMed ID: 26659344 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]